Tags

Type your tag names separated by a space and hit enter

ACP Journal Club. Nateglinide did not reduce diabetes or CV events in patients with impaired glucose tolerance and CV risk factors.
Ann Intern Med 2010; 152(12):JC6-10AIM

Authors+Show Affiliations

Mount Sinai Medical Center, New York, NY, USA.

Pub Type(s)

Comment
Journal Article

Language

eng

PubMed ID

20547892

Citation

Farkouh, Michael. "ACP Journal Club. Nateglinide Did Not Reduce Diabetes or CV Events in Patients With Impaired Glucose Tolerance and CV Risk Factors." Annals of Internal Medicine, vol. 152, no. 12, 2010, pp. JC6-10.
Farkouh M. ACP Journal Club. Nateglinide did not reduce diabetes or CV events in patients with impaired glucose tolerance and CV risk factors. Ann Intern Med. 2010;152(12):JC6-10.
Farkouh, M. (2010). ACP Journal Club. Nateglinide did not reduce diabetes or CV events in patients with impaired glucose tolerance and CV risk factors. Annals of Internal Medicine, 152(12), pp. JC6-10. doi:10.7326/0003-4819-152-12-201006150-02010.
Farkouh M. ACP Journal Club. Nateglinide Did Not Reduce Diabetes or CV Events in Patients With Impaired Glucose Tolerance and CV Risk Factors. Ann Intern Med. 2010 Jun 15;152(12):JC6-10. PubMed PMID: 20547892.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - ACP Journal Club. Nateglinide did not reduce diabetes or CV events in patients with impaired glucose tolerance and CV risk factors. A1 - Farkouh,Michael, PY - 2010/6/16/entrez PY - 2010/6/16/pubmed PY - 2010/6/16/medline SP - JC6 EP - 10 JF - Annals of internal medicine JO - Ann. Intern. Med. VL - 152 IS - 12 SN - 1539-3704 UR - https://www.unboundmedicine.com/medline/citation/20547892/ACP_Journal_Club__Nateglinide_did_not_reduce_diabetes_or_CV_events_in_patients_with_impaired_glucose_tolerance_and_CV_risk_factors_ L2 - https://www.annals.org/article.aspx?doi=10.7326/0003-4819-152-12-201006150-02010 DB - PRIME DP - Unbound Medicine ER -